tetano
Editor, Senior Moderator
J Emerg Med
. 2021 Sep 27;S0736-4679(21)00733-2.
doi: 10.1016/j.jemermed.2021.09.017. Online ahead of print.
STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine
Michael Azir[SUP] 1 [/SUP], Brannon Inman[SUP] 2 [/SUP], James Webb[SUP] 2 [/SUP], Lloyd Tannenbaum[SUP] 2 [/SUP]
Affiliations
Abstract
Background: In May 2021, the U.S. Food and Drug Administration expanded the Emergency Use Authorization for the Pfizer-BioNTech mRNA Coronavirus disease 2019 (COVID-19) Vaccine (BNT162b2) to include adolescents 12-15 years of age. As vaccine administration continues to increase, potential adverse outcomes, to include myocarditis, are being reported to the Vaccine Adverse Event Reporting System.
Case report: This case report describes a 17-year-old male patient who developed focal myocarditis mimicking an ST-segment elevation myocardial infarction (STEMI) 3 days after administration of an mRNA COVID-19 vaccine. Why Should an Emergency Physician Be Aware of This? Myocarditis is a rare complication in adolescents receiving mRNA COVID-19 vaccines. Focal myocarditis may demonstrate localizing electrocardiographic changes consistent with a STEMI. Overall, complications of the mRNA COVID-19 vaccines are extremely rare. The vaccine continues to be recommended by public health experts, as the benefits of vaccinations greatly outweigh the rare side effects.
Keywords: BNT162b2; COVID-19; STEMI; mRNA vaccine; myocarditis.
. 2021 Sep 27;S0736-4679(21)00733-2.
doi: 10.1016/j.jemermed.2021.09.017. Online ahead of print.
STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine
Michael Azir[SUP] 1 [/SUP], Brannon Inman[SUP] 2 [/SUP], James Webb[SUP] 2 [/SUP], Lloyd Tannenbaum[SUP] 2 [/SUP]
Affiliations
- PMID: 34756746
- PMCID: PMC8469220
- DOI: 10.1016/j.jemermed.2021.09.017
Abstract
Background: In May 2021, the U.S. Food and Drug Administration expanded the Emergency Use Authorization for the Pfizer-BioNTech mRNA Coronavirus disease 2019 (COVID-19) Vaccine (BNT162b2) to include adolescents 12-15 years of age. As vaccine administration continues to increase, potential adverse outcomes, to include myocarditis, are being reported to the Vaccine Adverse Event Reporting System.
Case report: This case report describes a 17-year-old male patient who developed focal myocarditis mimicking an ST-segment elevation myocardial infarction (STEMI) 3 days after administration of an mRNA COVID-19 vaccine. Why Should an Emergency Physician Be Aware of This? Myocarditis is a rare complication in adolescents receiving mRNA COVID-19 vaccines. Focal myocarditis may demonstrate localizing electrocardiographic changes consistent with a STEMI. Overall, complications of the mRNA COVID-19 vaccines are extremely rare. The vaccine continues to be recommended by public health experts, as the benefits of vaccinations greatly outweigh the rare side effects.
Keywords: BNT162b2; COVID-19; STEMI; mRNA vaccine; myocarditis.